Oxygen Biotherapeutics, Inc. (OTC BB: OXBO)

Oxygen Biotherapeutics, Inc. (OTC BB: OXBO), previously known as Synthetic Blood International, Inc., is focused on transforming patient care through the development of advanced oxygen-based therapies using Oxycyte®, the company’s perfluorocarbon (PFC) therapeutic oxygen carrier, and other solutions. Oxycyte could potentially be used in numerous indications, including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. For further information, visit the Company’s web site at www.oxybiomed.com.